Clinical Trial Update: Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating fulvestrant with or without lapatinib in postmenopausal women with hormone receptor–positive, HER2-positive advanced breast cancer; stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)
• Lapatinib (Lapatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Estrogen Receptor Positive, HER2 Positive Breast Carcinoma | Phase 3 | Status: COMPLETED | Results posted: 2015-06-17